Anti-inflammatory properties of desipramine and fluoxetine

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Roumestan, Caroline ^a,b,d   Michel, Alain ^b   Bichon, Florence ^b   Portet, Karine ^b   Detoc, Maëlle ^a   Henriquet, Corinne ^a   Jaffuel, Dany ^c   Mathieu, Marc ^a  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c Centre Médical Spécialisé de Pneumologie   (France)

^d Laboratoires Macors   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE; DESIPRAMINE; FLUOXETINE; PREDNISOLONE;

ANIMAL; ARTICLE; ASTHMA; BAGG ALBINO MOUSE; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; HUMAN; INFLAMMATION; METABOLISM; MONOCYTE; MOUSE; RAT; RESPIRATORY TRACT MUCOSA; SEPTIC SHOCK; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; ASTHMA; CELLS, CULTURED; CYTOKINES; DESIPRAMINE; DISEASE MODELS, ANIMAL; FLUOXETINE; HUMANS; INFLAMMATION; MICE; MICE, INBRED BALB C; MONOCYTES; PREDNISOLONE; RATS; RESPIRATORY MUCOSA; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 34447092167     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-35     Document Type: Article

References (35)

1. Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25(4):767-780. 10.1016/S0278-5846(01)00155-5, 11383977.
2. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(2):201-217. 10.1016/j.pnpbp.2004.11.003, 15694227.
3. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999, 4(4):317-327. 10.1038/sj.mp.4000586, 10483047.
4. Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 2002, 16(5):569-574. 10.1016/S0889-1591(02)00008-9, 12401470.
5. Ignatowski TA, Noble BK, Wright JR, Gorfien JL, Heffner RR, Spengler RN. Neuronal-associated tumor necrosis factor (TNF[alpha]): its role in noradrenergic functioning and modification of its expression following antidepressant drug administration. Journal of Neuroimmunology 1997, 79(1):84-90. 10.1016/S0165-5728(97)00107-0, 9357451.
6. Reynolds JL, Ignatowski TA, Sud R, Spengler RN. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005, 133(2):519-531. 10.1016/j.neuroscience.2005.02.023, 15878644.
7. Reynolds JL, Ignatowski TA, Sud R, Spengler RN. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. J Pharmacol Exp Ther 2004, 310(3):1216-1225. 10.1124/jpet.104.067835, 15082752.
8. Bianchi M, Sacerdote P, Panerai AE. Chlomipramine differently affects inflammatory edema and pain in the rat. Pharmacol Biochem Behav 1994, 48(4):1037-1040. 10.1016/0091-3057(94)90217-8, 7972282.
9. Bianchi M, Sacerdote P, Panerai AE. Fluoxetine reduces inflammatory edema in the rat: involvement of the pituitary-adrenal axis. Eur J Pharmacol 1994, 263(1 - 2):81-84. 10.1016/0014-2999(94)90526-6, 7821365.
10. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 2006, 6(6):903-907. 10.1016/j.intimp.2005.12.007, 16644475.
11. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994, 151(7):979-986.
12. Hurwitz EL, Morgenstern H. Cross-sectional associations of asthma, hay fever, and other allergies with major depression and low-back pain among adults aged 20 - 39 years in the United States. Am J Epidemiol 1999, 150(10):1107-1116.
13. Zielinski TA, Brown ES, Nejtek VA, Khan DA, Moore JJ, Rush AJ. Depression in Asthma: Prevalence and Clinical Implications. Prim Care Companion J Clin Psychiatry 2000, 2(5):153-158. 181132, 15014636.
14. Nejtek VA, Brown ES, Khan DA, Moore JJ, Van Wagner J, Perantie DC. Prevalence of mood disorders and relationship to asthma severity in patients at an inner-city asthma clinic. Ann Allergy Asthma Immunol 2001, 87(2):129-133.
15. Brown ES, Khan DA, Mahadi S. Psychiatric diagnoses in inner city outpatients with moderate to severe asthma. Int J Psychiatry Med 2000, 30(4):319-327.
16. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kB. Annu Rev Cell Biol 1994, 10:405-455. 10.1146/annurev.cb.10.110194.002201, 7888182.
17. Moriuchi H, Moriuchi M, Fauci AS. Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol 1997, 158(7):3483-3491.
18. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH, Kerwin RW. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 2001, 134(6):1335-1343. 10.1038/sj.bjp.0704368, 11704655.
19. Mathieu M, Gougat C, Jaffuel D, Danielsen M, Godard P, Bousquet J, Demoly P. The glucocorticoid receptor gene as a candidate for gene therapy in asthma. Gene Ther 1999, 6:245-252. 10.1038/sj.gt.3300814, 10435109.
20. Tamura T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. The effects of antidepressant drug treatments on activator protein-1 binding activity in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26(2):375-381. 10.1016/S0278-5846(01)00286-X, 11817516.
21. Okamoto H, Shino Y, Hashimoto K, Kumakiri C, Shimizu E, Shirasawa H, Iyo M. Dynamic changes in AP-1 transcription factor DNA binding activity in rat brain following administration of antidepressant amitriptyline and brain-derived neurotrophic factor. Neuropharmacology 2003, 45(2):251-259. 10.1016/S0028-3908(03)00148-5, 12842131.
22. Post A, Crochemore C, Uhr M, Holsboer F, Behl C. Differential induction of NF-kappaB activity and neural cell death by antidepressants in vitro. Eur J Neurosci 2000, 12(12):4331-4337. 10.1046/j.0953-816X.2000.01352.x, 11122343.
23. Donovan CE, Mark DA, He HZ, Liou HC, Kobzik L, Wang Y, De Sanctis GT, Perkins DL, Finn PW. NF-kappa B/Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation. J Immunol 1999, 163(12):6827-6833.
24. Nguyen C, Teo JL, Matsuda A, Eguchi M, Chi EY, Henderson W, Kahn M. Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc Natl Acad Sci USA 2003, 100(3):1169-1173. 298745, 12552119, 10.1073/pnas.0437889100.
25. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, Bottiger BW, Stern DM, Waldherr R, Saeger HD, et al. Role of NF-kappaB in the mortality of sepsis. J Clin Invest 1997, 100(5):972-985. 508272, 9276714.
26. Glotzbach RK, Preskorn SH. Brain concentrations of tricyclic antidepressants:single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology (Berl) 1982, 78(1):25-27. 10.1007/BF00470582, 6815692.
27. Orsulak PJ, Kenney JT, Debus JR, Crowley G, Wittman PD. Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversedphase HPLC with ultraviolet detection. Clin Chem 1988, 34(9):1875-1878.
28. Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 2004, 64(20):7562-7569. 10.1158/0008-5472.CAN-03-4046, 15492283.
29. Kavallaris M, Kuo D, Burkhart C, Regl D, Norris M, Haber M, Horwitz S. Taxolresistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997, 100:1282-1293. 508306, 9276747.
30. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004, 255(3):320-331. 10.1111/j.1365-2796.2003.01302.x, 14871456.
31. Sacerdote P, Bianchi M, Panerai AE. Chlorimipramine and nortriptyline but not fluoxetine and fluvoxamine inhibit human polymorphonuclear cell chemotaxis in vitro. Gen Pharmacol 1994, 25(3):409-412.
32. Les ventes d'antidépresseurs entre 1980 et 2001. , http://www.sante.gouv.fr/drees/etude-resultat/er-pdf/er285.pdf
33. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): Relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Care & Research 2006, 55(4):628-635.
34. Lechin F, van der Dijs B, Orozco B, Jara H, Rada I, Lechin ME, Lechin AE. The serotonin uptake-enhancing drug tianeptine suppresses asthmatic symptoms in children: a double-blind, crossover, placebo-controlled study. J Clin Pharmacol 1998, 38(10):918-925.
35. Brown ES, Vigil L, Khan DA, Liggin JD, Carmody TJ, Rush AJ. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study. Biol Psychiatry 2005, 58(11):865-870. 10.1016/j.biopsych.2005.04.030, 15993860.